Abdominal obesity and hyperglycemia mask the effect of a common APOC3 haplotype on the risk of myocardial infarction

American Journal of Clinical Nutrition

Volumn 87, Issue 6, 2008, Pages 1932-1938

  Ruiz Narváez, Edward A ^a   Sacks, Frank M ^a   Campos, Hannia ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; GLUCOSE;

ABDOMINAL OBESITY; ADULT; APOC3 GENE; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE; GENE MUTATION; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE;

EID: 45749155917     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/87.6.1932     Document Type: Article

References (36)

1. Alaupovic P, Mack WJ, Knight-Gibson C, Hodis HN. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol 1997;17:715-22.
2. Sacks FM, Alaupovic P, Moye LA, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial Circulation 2000;102:1886-92.
3. Windler E, Chao Y, Havel RJ. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat. J Biol Chem 1980;255:5475-80.
4. Sehayek E, Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem 1991;266:18259-67.
5. Aalto-Setala K, Fisher EA, Chen X, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 1992;90:1889-900.
6. de Silva HV, Lauer SJ, Wang J, et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem 1994;269:2324-35.
7. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein CIII containing triglyceride-rich lipoproteins contributing to formation of LDL subfractions. J Lipid Res 2007.
8. Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 2006;113:691-700.
9. Kawakami A, Aikawa M, Nitta N, Yoshida M, Libby P, Sacks FM. Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitiveGprotein- and protein kinase C alpha-mediated nuclear factor-kappaB activation. Arterioscler Thromb Vasc Biol 2007;27:219-25.
10. Ordovas JM, Civeira F, Genest J Jr, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus relationships with lipids, apolipoproteins, and premature coronary artery disease Atherosclerosis 1991;87:75-86.
11. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996;16:941-7.
12. Li WW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995;96:2601-5.
13. Olivieri O, Stranieri C, Bassi A, et al. ApoC-III gene polymorphisms and risk of coronary artery disease. J Lipid Res 2002;43:1450-7.
14. Tilly P, Sass C, Vincent-Viry M, Aguillon D, Siest G, Visvikis S. Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas Cohort. J Lipid Res 2003;44:430-6.
15. Olivieri O, Bassi A, Stranieri C, et al. Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease. J Lipid Res 2003;44: 2374-81.
16. Ferns GA, Stocks J, Ritchie C, Galton DJ. Genetic polymorphisms of apolipoprotein C-III and insulin in survivors of myocardial infarction. Lancet 1985;2:300-3.
17. Ruiz-Narvaez EA, Yang Y, Nakanishi Y, Kirchdorfer J, Campos H. APOC3/A5 haplotypes, lipid levels, and risk of myocardial infarction in the Central Valley of Costa Rica. J Lipid Res 2005;46:2605-13.
18. Esterbauer H, Hell E, Krempler F, Patsch W. Allele-specific differences in apolipoprotein C-III mRNA expression in human liver. Clin Chem 1999;45:331-9.
19. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996;271:665-8.
20. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000;275:9047-54.
21. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006;119(suppl):S10-6.
22. Campos H, Bailey SM, Gussak LS, Siles X, Ordovas JM, Schaefer EJ. Relations of body habitus, fitness level, and cardiovascular risk factors including lipoproteins and apolipoproteins in a rural and urban Costa Rican population. Arterioscler Thromb 1991;11:1077-88.
23. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(suppl):S5-20.
24. Zaykin DV, Westfall PH, Young SS, Karnoub MA, Wagner MJ, Ehm MG.Testing association of statistically inferred haplotypes with discrete and continuous traits in samples of unrelated individuals. Hum Hered 2002;53:79-91.
25. Stram DO, Leigh Pearce C, Bretsky P, et al. Modeling and E-M estimation of haplotype-specific relative risks from genotype data for a casecontrol study of unrelated individuals. Hum Hered 2003;55:179-90.
26. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-23.
27. Russo GT, Meigs JB, Cupples LA, et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001;158:173-81.
28. Wong WM, Hawe E, Li LK, et al. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res 2003;92:969-75.
29. Grundy SM, Brewer HB Jr, Cleeman JI, Smith S, J., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 2004;109:433-8.
30. Onuma H, Vander Kooi BT, Boustead JN, Oeser JK, O'Brien RM. Correlation between FOXO1a (FKHR) and FOXO3a (FKHRL1) binding and the inhibition of basal glucose-6-phosphatase catalytic subunit gene transcription by insulin. Mol Endocrinol 2006;20:2831-47.
31. Vander Kooi BT, Streeper RS, Svitek CA, Oeser JK, Powell DR, O'Brien RM. The three insulin response sequences in the glucose-6-phosphatase catalytic subunit gene promoter are functionally distinct. J Biol Chem 2003;278:11782-93.
32. O'Brien RM, Streeper RS, Ayala JE, Stadelmaier BT, Hornbuckle LA. Insulin-regulated gene expression. Biochem Soc Trans 2001;29:552-8.
33. Streeper RS, Svitek CA, Chapman S, Greenbaum LE, Taub R, O'Brien RM. A multicomponent insulin response sequence mediates a strong repression of mouse glucose-6-phosphatase gene transcription by insulin. J Biol Chem 1997;272:11698-701.
34. Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Invest 2004;114:1493-503.
35. Zhang W, Patil S, Chauhan B, et al. FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem 2006;281:10105-17.
36. Dickens M, Svitek CA, Culbert AA, O'Brien RM, Tavare JM. Central role for phosphatidylinositide 3-kinase in the repression of glucose-6-phosphatase gene transcription by insulin. J Biol Chem 1998;273: 20144-9.